S&P 500   4,298.86 (+0.11%)
DOW   33,876.78 (+0.13%)
QQQ   354.50 (+0.38%)
AAPL   180.96 (+0.22%)
MSFT   326.79 (+0.47%)
META   264.95 (+0.14%)
GOOGL   122.23 (+0.07%)
AMZN   123.43 (-0.66%)
TSLA   244.40 (+4.06%)
NVDA   387.70 (+0.68%)
NIO   7.74 (-0.64%)
BABA   85.50 (-0.74%)
AMD   124.92 (+3.20%)
T   15.96 (-0.75%)
F   13.74 (+1.18%)
MU   65.43 (+0.17%)
CGC   0.68 (-1.45%)
GE   106.30 (+0.22%)
DIS   91.95 (-0.63%)
AMC   4.77 (+1.92%)
PFE   38.97 (-0.31%)
PYPL   63.49 (-1.17%)
NFLX   420.02 (+2.60%)
S&P 500   4,298.86 (+0.11%)
DOW   33,876.78 (+0.13%)
QQQ   354.50 (+0.38%)
AAPL   180.96 (+0.22%)
MSFT   326.79 (+0.47%)
META   264.95 (+0.14%)
GOOGL   122.23 (+0.07%)
AMZN   123.43 (-0.66%)
TSLA   244.40 (+4.06%)
NVDA   387.70 (+0.68%)
NIO   7.74 (-0.64%)
BABA   85.50 (-0.74%)
AMD   124.92 (+3.20%)
T   15.96 (-0.75%)
F   13.74 (+1.18%)
MU   65.43 (+0.17%)
CGC   0.68 (-1.45%)
GE   106.30 (+0.22%)
DIS   91.95 (-0.63%)
AMC   4.77 (+1.92%)
PFE   38.97 (-0.31%)
PYPL   63.49 (-1.17%)
NFLX   420.02 (+2.60%)
S&P 500   4,298.86 (+0.11%)
DOW   33,876.78 (+0.13%)
QQQ   354.50 (+0.38%)
AAPL   180.96 (+0.22%)
MSFT   326.79 (+0.47%)
META   264.95 (+0.14%)
GOOGL   122.23 (+0.07%)
AMZN   123.43 (-0.66%)
TSLA   244.40 (+4.06%)
NVDA   387.70 (+0.68%)
NIO   7.74 (-0.64%)
BABA   85.50 (-0.74%)
AMD   124.92 (+3.20%)
T   15.96 (-0.75%)
F   13.74 (+1.18%)
MU   65.43 (+0.17%)
CGC   0.68 (-1.45%)
GE   106.30 (+0.22%)
DIS   91.95 (-0.63%)
AMC   4.77 (+1.92%)
PFE   38.97 (-0.31%)
PYPL   63.49 (-1.17%)
NFLX   420.02 (+2.60%)
S&P 500   4,298.86 (+0.11%)
DOW   33,876.78 (+0.13%)
QQQ   354.50 (+0.38%)
AAPL   180.96 (+0.22%)
MSFT   326.79 (+0.47%)
META   264.95 (+0.14%)
GOOGL   122.23 (+0.07%)
AMZN   123.43 (-0.66%)
TSLA   244.40 (+4.06%)
NVDA   387.70 (+0.68%)
NIO   7.74 (-0.64%)
BABA   85.50 (-0.74%)
AMD   124.92 (+3.20%)
T   15.96 (-0.75%)
F   13.74 (+1.18%)
MU   65.43 (+0.17%)
CGC   0.68 (-1.45%)
GE   106.30 (+0.22%)
DIS   91.95 (-0.63%)
AMC   4.77 (+1.92%)
PFE   38.97 (-0.31%)
PYPL   63.49 (-1.17%)
NFLX   420.02 (+2.60%)
NASDAQ:BLTE

Belite Bio (BLTE) Competitors

$15.03
+0.23 (+1.55%)
(As of 06/9/2023 ET)
Compare
Today's Range
$14.60
▼
$15.35
50-Day Range
$14.80
▼
$30.20
52-Week Range
$14.22
▼
$44.70
Volume
45,979 shs
Average Volume
19,233 shs
Market Capitalization
$374.55 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$56.00
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media

BLTE vs. MLYS, ACRS, TYRA, TERN, TSVT, MCRB, HROW, EWTX, GNLX, and BTAI

Should you be buying Belite Bio stock or one of its competitors? The main competitors of Belite Bio include Mineralys Therapeutics (MLYS), Aclaris Therapeutics (ACRS), Tyra Biosciences (TYRA), Terns Pharmaceuticals (TERN), 2seventy bio (TSVT), Seres Therapeutics (MCRB), Harrow Health (HROW), Edgewise Therapeutics (EWTX), Genelux (GNLX), and BioXcel Therapeutics (BTAI). These companies are all part of the "pharmaceutical preparations" industry.

Belite Bio vs.

Mineralys Therapeutics (NASDAQ:MLYS) and Belite Bio (NASDAQ:BLTE) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, valuation, community ranking, media sentiment, profitability, risk, dividends, earnings and institutional ownership.

Company Net Margins Return on Equity Return on Assets
Mineralys Therapeutics N/A N/A N/A
Belite Bio N/A N/A N/A

Mineralys Therapeutics currently has a consensus price target of $36.20, suggesting a potential upside of 144.26%. Belite Bio has a consensus price target of $56.00, suggesting a potential upside of 272.59%. Given Belite Bio's higher probable upside, analysts plainly believe Belite Bio is more favorable than Mineralys Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Mineralys Therapeutics
0 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
3.00
Belite Bio
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Mineralys TherapeuticsN/AN/A-$29.80 millionN/AN/A
Belite BioN/AN/A-$12.65 millionN/AN/A

Mineralys Therapeutics received 1 more outperform votes than Belite Bio when rated by MarketBeat users. Likewise, 100.00% of users gave Mineralys Therapeutics an outperform vote while only 85.71% of users gave Belite Bio an outperform vote.

CompanyUnderperformOutperform
Mineralys TherapeuticsOutperform Votes
7
100.00%
Underperform Votes
No Votes
Belite BioOutperform Votes
6
85.71%
Underperform Votes
1
14.29%

0.5% of Belite Bio shares are held by institutional investors. 13.3% of Belite Bio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Belite Bio had 12 more articles in the media than Mineralys Therapeutics. MarketBeat recorded 13 mentions for Belite Bio and 1 mentions for Mineralys Therapeutics. Belite Bio's average media sentiment score of 0.32 beat Mineralys Therapeutics' score of 0.00 indicating that Belite Bio is being referred to more favorably in the news media.

Company Overall Sentiment
Mineralys Therapeutics Neutral
Belite Bio Neutral

Summary

Belite Bio beats Mineralys Therapeutics on 6 of the 9 factors compared between the two stocks.


New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BLTE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BLTE vs. The Competition

Export to Excel
MetricBelite BioPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$374.55M$5.95B$4.59B$6.29B
Dividend YieldN/A2.59%2.27%6.19%
P/E RatioN/A6.20100.6813.44
Price / SalesN/A333.363,374.0588.76
Price / CashN/A20.9592.19113.59
Price / Book9.004.774.695.30
Net Income-$12.65M$194.45M$118.07M$193.23M
7 Day Performance-12.36%0.50%0.90%1.51%
1 Month Performance-40.36%0.95%1.53%5.17%
1 Year Performance-7.73%17.91%8.63%3.11%

Belite Bio Competitors List

Export to Excel
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
MLYS
Mineralys Therapeutics
1.632 of 5 stars		$14.31
+1.6%		$36.20
+153.0%		N/A$584.66MN/A0.00N/A
ACRS
Aclaris Therapeutics
2.0195 of 5 stars		$8.19
-1.2%		$32.00
+290.7%		-40.0%$578.87M$29.75M-5.6972Positive News
TYRA
Tyra Biosciences
1.9408 of 5 stars		$14.02
+0.5%		$21.00
+49.8%		+110.7%$596.69MN/A-11.2225Positive News
High Trading Volume
TERN
Terns Pharmaceuticals
2.1942 of 5 stars		$10.56
-2.7%		$14.67
+38.9%		+530.3%$598.44M$1M-6.6441Analyst Report
TSVT
2seventy bio
2.0079 of 5 stars		$11.93
-0.4%		$29.00
+143.1%		-7.6%$598.89M$91.50M-2.18437Positive News
MCRB
Seres Therapeutics
2.0036 of 5 stars		$4.70
-0.6%		$14.00
+197.9%		+45.1%$601.13M$7.13M-2.04333
HROW
Harrow Health
2.2226 of 5 stars		$19.16
-4.7%		$30.47
+59.0%		+173.1%$605.75M$92.58M-29.48182Positive News
EWTX
Edgewise Therapeutics
1.5493 of 5 stars		$9.75
-2.8%		$17.00
+74.4%		+54.5%$616.98MN/A-7.3331Positive News
GNLX
Genelux
1.5417 of 5 stars		$25.06
+4.4%		$10.00
-60.1%		N/A$618.23M$11.07M0.00N/APositive News
BTAI
BioXcel Therapeutics
2.4992 of 5 stars		$18.94
+0.4%		$50.29
+165.5%		+74.1%$552.29M$581,000.00-2.8689

Related Companies and Tools

Related Companies:
Top 10 Stock Comparisons
This page (NASDAQ:BLTE) was last updated on 6/9/2023 by MarketBeat.com Staff

My Account -